- Home
- MGEE vs HCM Comparison
MGEE vs HCM Comparison
Compare MGEE & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGEE
- HCM
- Stock Information
- Founded
- MGEE 1855
- HCM 2000
- Country
- MGEE United States
- HCM Hong Kong
- Employees
- MGEE N/A
- HCM N/A
- Industry
- MGEE Electric Utilities: Central
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- MGEE Energy
- HCM Health Care
- Exchange
- MGEE Nasdaq
- HCM Nasdaq
- Market Cap
- MGEE 3.1B
- HCM 2.6B
- IPO Year
- MGEE N/A
- HCM N/A
- Fundamental
- Price
- MGEE $87.00
- HCM $14.66
- Analyst Decision
- MGEE Sell
- HCM Sell
- Analyst Count
- MGEE 2
- HCM 1
- Target Price
- MGEE $79.00
- HCM $13.75
- AVG Volume (30 Days)
- MGEE 116.7K
- HCM 44.7K
- Earning Date
- MGEE 11-10-2025
- HCM 08-07-2025
- Dividend Yield
- MGEE 2.19%
- HCM N/A
- EPS Growth
- MGEE 12.86
- HCM N/A
- EPS
- MGEE 3.60
- HCM 0.53
- Revenue
- MGEE $701,317,000.00
- HCM $602,197,000.00
- Revenue This Year
- MGEE $10.30
- HCM N/A
- Revenue Next Year
- MGEE $3.28
- HCM $15.49
- P/E Ratio
- MGEE $24.12
- HCM $5.56
- Revenue Growth
- MGEE 8.61
- HCM N/A
- 52 Week Low
- MGEE $81.14
- HCM $11.51
- 52 Week High
- MGEE $109.22
- HCM $21.25
- Technical
- Relative Strength Index (RSI)
- MGEE 62.04
- HCM 36.94
- Support Level
- MGEE $84.05
- HCM $14.86
- Resistance Level
- MGEE $87.94
- HCM $15.34
- Average True Range (ATR)
- MGEE 1.45
- HCM 0.34
- MACD
- MGEE 0.41
- HCM -0.07
- Stochastic Oscillator
- MGEE 83.08
- HCM 11.11
About MGEE MGE Energy Inc
MGE Energy provides electric service to 161,000 customers and natural gas service to 173,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.